<DOC>
	<DOC>NCT01823822</DOC>
	<brief_summary>This multicentre, randomised, double-blind, 2-parallel group, controlled trial aims to investigate whether oral milk protein supplements led to increase in serum Insulin-like Growth Factor-I levels (IGF-I) as compared with a control group fed with an iso-caloric supplement, in women with anorexia nervosa. Subjects receive either 150g/day of tested product or control product for 4-week, followed by a 4-week follow-up.</brief_summary>
	<brief_title>Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa</brief_title>
	<detailed_description>Study centres: 4 active centres in France and 2 active centres in Switzerland</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Women aged between 18 to 40 years (bounds included). Women with a serum IGFI level below the 25th percentile of the reference value according to the age (bounds included). Women who had given written inform consent. Women with DSMIVconfirmed anorexia nervosa lasting for at least 6 months. Women with concomitant binge eating and purging type are also included. Women admitted inhospital for weight and nutritional rehabilitation. It is anticipated that the patient will stay inhospital during the full duration of the 4week supplementation phase, and at least 5 weeks within the study. Women being already regular consumers of dairy products. For women with childbearing potential, use of a contraceptive method. Discontinuation of any mineral and vitamin supplements containing calcium and vitamin D, 1 week before starting the product consumption and during the study. Women with primary amenorrhea; Women with lactose intolerance; Women with any other metabolic disease that could affect bone metabolism: osteogenesis imperfecta, Paget's disease of bone, hyperthyroidism, primary hyperparathyroidism; Women with current or past neoplasm; Women with any other severe comorbidity; Pregnant or breast feeding women; Women with epilepsy; Women with any current or past use of the following treatments: bisphosphonates, calcitonin, steroids; Patients enrolled in another clinical study within the last 4 weeks; Patients having already received oral nutritional supplements or who need to receive other oral or intravenous (IV) supplements during the followup; Patients having received oral or IV nutritional supplements within two weeks before the inclusion; Patients having willed to participate in another clinical study during the present study phase and 4 weeks after the end of their participation in the present study.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Anorexia nervosa</keyword>
	<keyword>Protein supplements</keyword>
	<keyword>IGF-I</keyword>
</DOC>